In response to changing mandatory guidelines for federal workplace drug testing in the US, Agilent Technologies and South Bend Medical Foundation have developed new urine testing methods.
In response to changing mandatory guidelines for federal workplace drug testing in the US, Agilent Technologies and South Bend Medical Foundation have developed new urine testing methods. For the first time, the guidelines will allow for the use of liquid chromatography–triple quadrupole mass spectrometry (LC–MS–MS) for confirmatory urine drug testing.
“We frequently hear that the main barriers to adopting the new technologies required to drive laboratory productivity and/or cost reductions are lack of time and in-house expertise,” said Tom Gluodenis, Jr, Agilent worldwide forensics programme manager. “The tools we have just developed in response to the changing workplace guidelines could enable laboratories to validate these methods and be running billable urine confirmations in under 60 days.”
Use of LC–MS–MS for urine drug confirmations is reported to speed testing and reduce cost-per-sample compared with previous methods. In addition, several new target drugs have been added to the panel, several cut‑off concentrations have been adjusted, and the minimum requirements for interference testing have been satisfied for amphetamines and opiates. Also, the new requirement specifying at least 10 data points across a peak can be met.
For more information visit www.agilent.com